Fragment-based Drug Delivery Market Overview

The global Fragment-based drug delivery market is estimated to be worth over USD 3.12Bn in 2033 and is expected to grow at CAGR of 11% during the forecast period (2024-2033). Fragment-based drug delivery portrays a state-of-the-art approach in the pharmaceutical sphere, geared up to modify the global outlook of drug development. This groundbreaking strategy centers on using small, molecular fragments as the substructure for drug design, allowing a more explicit and targeted approach to therapeutic intervention. Unlike conventionaltechniques, fragment-based drug delivery leverages the morals of structural biology, practicing fragments that attach to particular biological targets with high rapport. The global market for fragment-based drug delivery is gaining traction, encouraged by its potential to align the drug discovery process and establish more effective treatments.

A leading driver in the adoption of fragment-based drug delivery is its capability to navigate the intricacies of drug development. By beginning with smaller, high-affinity fragments, researchers can methodically build upon these elemental units, maximizing drug candidates for improved efficiency. This approach not only fuels the drug development timeline but also increments the likelihood of success in clinical trials. Along with that, fragment-based drug discovery streamlines with the industry's quest of precision medicine, assisting the design of customized therapeutics based on individual patient profiles.

Since the global pharmaceutical panorama embraces this revolutionary methodology, leading players in the market are making substantial strides. Companies like Astex Pharmaceuticals and Charles River Laboratories are in the lead of fragment-based drug discovery, contributing to the development of new treatments. The market's growth is further accelerated by collaborations between pharmaceutical companies and research institutions, bringing up a synergistic environment for progressing this ingenious approach.

Thus, fragment-based drug delivery functions as a beam of innovation in drug development, encouraging more targeted, effective, and precision therapies. With the consistentdevelopment of this field, the global market is estimated to experiencesignificant growth, delivering a transformational shift that holds the potential to rethink the future of pharmaceuticals.

Figure 1. Fragment-based Drug Delivery: Market Size

Get more details on this report - Request Free Sample

Key Market Insights

Drug discovery and development is aintricate and tiresome process that needs a considerable amount of resources and capital investment. As a matter of fact, on a par with, the journey from the institution of primary proof-of-concept to commercial launch, is anticipated to take around 10-12 years. Nevertheless, only a little fraction of early-stage therapeutic candidates iscapable to make it past preclinical testing, into clinical evaluation.Considering thesoaring complexity in drug discovery research, the entire expenditure on pharmaceutical / biotechnology R&D has progressively increased over the years.

Regardless of severalbenefits, high-throughput screening (HTS) is a high-priced procedure and pharmacological leads produced via this process have been related to high attrition rates throughout the preclinical development.Fragment-based drug discovery (FBDD), is a comparativelynovel hit screening approach. which has been reflected to provide a number of advantages, including a cost advantage and the potential to allow the generation of hits with enhanced physiochemical properties, over HTS.

In that respect, it is worth pointing out that, three marketed drugs, namely Venetoclax (VENCLEXTA®), Vemurafenib (ZELBORAF®), and Erdafitinib (BALVERSA™), initiated from fragment-based library screens. About 40 candidates detectedthrough the FBDD approach are in clinical trials. In actual fact, at present, nearly 50% of discovery projects are anticipated to be using the FBDD approach, which utilizes biophysical methods such as X ray crystallography and nuclear magnetic resonance. In addition to that, the accessibility of bespoke fragment collections designed against individual biological targets / target families is estimated to facilitate the discovery of potent pharmaceutical leads against more challenging targets, such as protein-protein interactions and allosteric sites on enzymes. The fragment-based drug discovery market is projected to experiencenotable market growth over the forecast period.

Current Market Landscape:

The current circumstances of the global fragment-based drug delivery market represent a panorama of strong growth and game-changing advancements. Since pharmaceutical research ever more embraces innovative approaches, the market is undergoing a rise in interest and investment in fragment-based drug delivery. This technique, moored in structural biology, comprisesusing small molecular fragments as the foundation for drug design, fostering a more accurate and effective approach to therapeutic development.

The market's growth is accelerated by the efficiency of fragment-based drug delivery in tacklingconventional challenges in drug development. By commencing with small, high-affinity fragments, researchers can systematically construct drug candidates with enhanced specificity, accelerating the drug discovery process. This streamlined approach not only expedites timelines but also elevates the success rates in clinical trials, marking a paradigm shift in the industry.

Advancements in fragment-based drug delivery are further underscored by the active contributions of key players such as Astex Pharmaceuticals and Charles River Laboratories. These companies are at the forefront of pushing the boundaries of fragment-based drug discovery, contributing to the evolution of novel therapeutics. The ongoing collaborations between pharmaceutical entities and research institutions highlight a collective commitment to harnessing the full potential of this transformative approach.

The global fragment-based drug delivery market's ongoing trajectory coordinates with the industry's extensive shift toward precision medicine, enabling the creation of customized therapeutics on the basis of individual patient profiles. As these progressescarries on to remodel drug development strategies, the market stands poised for sustained growth, delivering a glimpse into a future where pharmaceutical innovation is characterized by efficiency, precision, and escalated therapeutic efficacy.

Market Dynamics

Market Drivers

Increasing Pursuit of Novel Medications to Address Intricate Medical Conditions

The soaringquest of novel drugs for the treatment of rare and intricate medical conditionsacts as a significant market driver for the global fragment-based drug delivery market. Since the pharmaceutical industry struggles with the complexities of resolvingintricate medical issues, there is a growing recognition that conventional drug discovery approaches are likely to fall short in delivering targeted and effective solutions. In this regard, fragment-based drug delivery has surfaced as a revolutionary strategy, delivering a more precise and systematic method for developing novel therapeutics.

The demand for innovative drugs to combatcomplicated medical problems, ranging from convoluted neurological disorders to multifaceted oncological problems, propels the adoption of fragment-based drug delivery. This approach enables researchers to methodically build drug candidates from small, high-affinity molecular fragments, maximizing their efficiency while minimizing potential adverseeffects. The exploration of novel drugs, exceptionally for conditions with unmet medical needs, accelerates pharmaceutical companies and researchers to invest in fragment-based drug discovery technologies. This rise in exploration not only fuels the market's growth but also locates fragment-based drug delivery as a crucial player in the quest for advanced, customized, and efficient therapeutics to address the complications of contemporary medical ailments.

Market Restraints

With regard to numerous advantages of fragment-based drug delivery, the market faces several challenges due to the unique characteristics and requirements associated with them. Some of the key market challenges include:

• Technical Concerns in Fragment Optimization: The process of maximizing small molecular fragments for drug development can pose technical conflicts, comprising issues associated with the fragment binding affinity and complexity, which is likely tohamper the efficacy of fragment-based drug delivery.
• Cost and Resource Intensiveness: Fragment-based drug discovery need significant resources and specialized expertise, contributing to towering costs in terms of both time and financial investments. This cost and resource intensiveness can be a hindrance, particularly for smaller pharmaceutical entities or research institutions with restricted budgets.

Market Opportunities

Application of Fragment-based Drug Delivery for the Development of Combination Therapies

The versatility of fragment-based drug discovery enables for the systematic investigation and maxmization of small molecular fragments, deliveringspecialized benefits in designing synergistic drug combinations. This opportunity is specifically relevant in the regard of complicated diseases with multifaceted molecular pathways, such as various cancers and infectious diseases.

Fragment-based drug delivery allows the determination of fragments that can optionally target various components of a disease pathway. This opens new horizons for forming combination therapies that address multiple aspects of a condition at the same time, potentially paving its way to improved therapeutic efficiency and mitigated likelihood of drug resistance. The capability to accurately customize drug combinations on the basis of characteristics of a particular disease or patient profile streamlines with the industry's increasingfocus on personalized medicine.

As pharmaceutical companies and researchers explore the potential of fragment-based drug delivery for combination therapies, the market has the opportunity to become a catalyst for a new era of innovative and more effective treatment regimens. This approach not only addresses the challenges of complex diseases but also positions fragment-based drug delivery as a cornerstone in the development of comprehensive and tailored therapeutic solutions.

Market Trends

• Increasing Emphasis on Targeted Therapeutics: The global fragment-based drug delivery market is witnessing a trend towards targeted therapeutics as researchers leverage this approach to design precise drugs tailored to specific molecular targets, enhancing therapeutic effectiveness.
• Rise in Collaborative Initiatives: Collaborative efforts between pharmaceutical companies, research institutions, and technology providers are on the rise, driving innovation and advancements in fragment-based drug delivery. Such partnerships contribute to a collective push for more efficient drug discovery processes and diversified applications of this methodology.

Fragment-based Drug Delivery Market: Key Segments

By Component

• Fragment Screening
  • Biophysical Techniques
    • NMR Spectroscopy
    • Differential Scanning Fluorimetry (DSF) Assay
    • Fluorescence Polarization
    • Isothermal Titration Calorimetry
    • X-ray Crystallography
    • Surface Plasmon Resonance (SPR)
    • Bilayer Interferometry
    • Mass Spectrometry (MS)
    • Capillary Electrophoresis
    • Weak Affinity Chromatography (WAC – HPLC – UV/MS)
    • Other Assay (biochemical)
  • Non-biophysical Techniques
• Fragment Optimization

By Application

• Oncology
• Central Nervous System (CNS) Disorders
• Infectious Diseases
• Cardiovascular Diseases
• Metabolic Disorders
• Inflammation & Autoimmune Diseases

By End User

• Academic & Research Institutions
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)

By Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Fragment-based Drug Delivery Market: Segmental Analysis

Based on component, the global fragment-based drug delivery market is divided into fragment screening and fragment optimization. The fragment screening segment is holding the largest share across the component type segment, as it comprises biophysical screening, computational screening among others. Fragment screening allows the exploration of a vast chemical space using small, low molecular weight compounds. These fragments can access unique binding sites on target proteins that larger molecules might not be able to reach, potentially leading to the discovery of novel binding modes and unprecedent drug leads.

Based on application, the global fragment-based drug delivery market includes oncology, Central Nervous System (CNS) disorders, infectious diseases, cardiovascular diseases, metabolic disorders, and inflammation & autoimmune diseases. The oncology segment is dominating the market, attributing to the specialized focus on cancer research and drug development. The major pharmaceutical companies have also escalated their investments in oncology-focused FBDD research and also initiated multiple collaborations with specialized FBDD providers.

Fragment-based Drug Delivery Market: Regional Analysis

North America is holding the largest share in the global fragment-based drug delivery marketdue to a combination of factors. Some of the major factors due to which region is dominating the market is significant investments by leading players in FBDD research & development, well-established infrastructure, and robust healthcare systems in the U.S. and Canada.

Figure 4. Fragment-based Drug Delivery Market: Distribution by Region

Get more details on this report - Request Free Sample

Leading Fragment-based Drug Delivery Developers

Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities associated with the fragment-based drug delivery market, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the biopharmaceutical industry. Key takeaways of the fragment-based drug delivery market are briefly discussed below. 

The report includes the list of players operating in the global fragment-based drug delivery market. Some of the key players include:

• Alveus Pharmaceuticals Pvt. Ltd.
• Astex Pharmaceuticals
• Beactica AB
• Charles River Laboratories International, Inc.
• Crown Bioscience, Inc.
• Evotec AG
• Emerald BioStructures, Inc.
• Kinetic Discovery Limited
• Proteros Fragments GmbH
• Sprint Bioscience
• Sygnature Discovery
• Structure Based Design, Inc.

Recent Developments in the Fragment-based Drug Delivery Market

Several recent developments have taken place in the field of fragment-based drug delivery, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we’ve outlined in our analysis chronologically.

• In August 2023, Astex Pharmaceuticals entered into research and license agreement with Merck with an aim to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer by applying its fragment-based drug discovery capability. 
• In April 2023, Daewoong Pharmaceutical announced the research agreement with Sygnature Discovery in order to discover a novel small molecule to target autoimmune diseases using fragment-based drug discovery and virtual high throughput screening. 
• In February 2023, Astex Pharmaceuticals collaborated with Cardiff University Medicines with an aim identify new drugs for the treatment of patients suffering from neurodegenerative diseases by leveraging fragment-based drug discovery platform.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the below table: